Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06188520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06188520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 5, 2023
Completion date
August 4, 2027
Enrollment
564 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

er+ her2- advanced breast cancer, high-grade serous ovarian cancer (hgsoc)